首页> 美国卫生研究院文献>Cardiovascular Research >Editors choice: microRNAs and HDL life cycle
【2h】

Editors choice: microRNAs and HDL life cycle

机译:编辑选择:microRNA和HDL生命周期

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

miRNAs have emerged as important regulators of lipoprotein metabolism. Work over the past few years has demonstrated that miRNAs control the expression of most of the genes associated with high-density lipoprotein (HDL) metabolism, including the ATP transporters, ABCA1 and ABCG1, and the scavenger receptor SRB1. These findings strongly suggest that miRNAs regulate HDL biogenesis, cellular cholesterol efflux, and HDL cholesterol (HDL-C) uptake in the liver, thereby controlling all of the steps of reverse cholesterol transport. Recent work in animal models has demonstrated that manipulating miRNA levels including miR-33 can increase circulating HDL-C. Importantly, antagonizing miR-33 in vivo enhances the regression and reduces the progression of atherosclerosis. These findings support the idea of developing miRNA inhibitors for the treatment of dyslipidaemia and related cardiovascular disorders such as atherosclerosis. This review article focuses on how HDL metabolism is regulated by miRNAs and how antagonizing miRNA expression could be a potential therapy for treating cardiometabolic diseases.
机译:miRNA已成为脂蛋白代谢的重要调节剂。过去几年的工作表明,miRNA控制着大多数与高密度脂蛋白(HDL)代谢相关的基因的表达,包括ATP转运蛋白,ABCA1和ABCG1以及清道夫受体SRB1。这些发现强烈表明,miRNA可调节肝脏中HDL的生物发生,细胞胆固醇外流和HDL胆固醇(HDL-C)的摄取,从而控制胆固醇逆向转运的所有步骤。动物模型的最新研究表明,操纵包括miR-33在内的miRNA的水平可以增加循环HDL-C的水平。重要的是,在体内拮抗miR-33可增强消退作用并减少动脉粥样硬化的进展。这些发现支持开发用于治疗血脂异常和相关心血管疾病(例如动脉粥样硬化)的miRNA抑制剂的想法。这篇综述文章重点讨论了miRNA如何调控HDL代谢,以及如何拮抗miRNA的表达可能是治疗心脏代谢疾病的潜在疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号